Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.
about
Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcerLiver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in miceImmunotherapy for tuberculosis: future prospectsProtective immunity to Mycobacterium tuberculosis infection by chemokine and cytokine conditioned CFP-10 differentiated dendritic cellsGenetic resistance of mice to Mycobacterium paratuberculosis is influenced by Slc11a1 at the early but not at the late stage of infectionInfluenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsT-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals.Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boostingGamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial.Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85BCD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.Improved tuberculosis DNA vaccines by formulation in cationic lipids.Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis.Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccinesDevelopment of luminescent Mycobacterium avium subsp. paratuberculosis for rapid screening of vaccine candidates in miceOn the use of DNA vaccines for the prophylaxis of mycobacterial diseases.Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccineWT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.How far have we reached in tuberculosis vaccine development?A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis.New vaccines against tuberculosis.Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferonBeyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.Immune responses to tuberculosis in developing countries: implications for new vaccines.Vaccines for bovine tuberculosis: current views and future prospects.DNA vaccines against mycobacterial diseases.BCG and BCG/DNAhsp65 vaccinations promote protective effects without deleterious consequences for experimental autoimmune encephalomyelitis.A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis.Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.Novel approaches to tuberculosis prevention: DNA vaccines.Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis.Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1.
P2860
Q24548647-87D858C6-6201-437A-A91B-0A1C98C677E4Q24652935-B5EFF38E-2A8C-4C6B-992C-FF4C9E1E6ADCQ26741261-1BD39CEC-CC3F-4EC5-BC4F-B72211354C8EQ28473223-21E47EB6-7097-4D97-8B21-C63734BE6DB0Q28506280-082B15DD-D813-4398-B6D9-8E8A4F6F5956Q28742787-1F0683BC-7A50-4F37-9FA4-BCFD93AA84DFQ33291869-41AC6B90-0801-4FFC-92DF-694C1C459E7BQ33324374-0DF377B0-5E32-43ED-8871-BEF129DC62B3Q33558303-07255EE1-FCD4-4EEF-9C72-DD49C66801D9Q33854478-AF638429-3C5A-4C7D-8D23-765C2F5F756EQ33946552-C5103315-8751-42D1-8F71-25BE1122824EQ34009351-9C823FD4-69AF-44E3-9932-84CB3C3829A8Q34033825-6530729F-DAD4-496D-9AE6-A83CD7904E3DQ34034104-852C8AC1-CA3F-487E-886D-3F66661A968DQ34126930-49E8D116-61C3-4FEF-9AF0-B5EE78F57548Q34484151-BD0581CA-579B-48DE-9A46-FC909789605AQ34527217-34467EF3-05A1-46D9-97B7-B9E2ED5A1F2AQ34601896-82D0AB8F-4EB0-45CD-B3D3-57F8F5BE001DQ34681116-E5C5B896-7132-4479-AD43-65172ACF171DQ34852418-21388F48-15A3-4611-A7FC-60850CC41DC0Q34940471-6FBC5FA1-C854-48F8-B0FF-159F13A0D63FQ34975671-BE7C3E7B-21FC-4096-9C3D-9E4A667A383CQ35052945-3DAAF034-BCF6-4732-92A7-545CD5FE9178Q35166856-CC643CFA-CB7A-4ECB-81EE-977CF5C09FCCQ35592360-4AEAF8C7-7B61-4D24-AF3A-F073AA246F41Q35801915-E32EFBB6-30EB-45D7-A389-5ABA6D4FA7DEQ35823534-BB35EC2D-60AA-4189-8F09-44402B79D001Q35949758-601B4434-EEE3-42A9-B51E-431C668BF5EFQ36071414-71C1EBFC-2895-4D9E-8BE0-7FE980DE465CQ36213975-86DB6D9B-F6C7-4800-B1D9-4F1F77220A7FQ36350586-6ED4A171-AA76-4F4A-9B17-2BBA02901E4CQ36895737-94060920-0135-4F40-A4F7-7A72F8D824F9Q37316205-7B9070D7-24A9-47ED-93BF-EFD00E0C1597Q37375963-B21355B7-D0AF-4A03-B918-B58CB7817D9EQ37451207-64C70EF7-C8D7-483F-BF1B-3B4F8EE748C2Q37582879-CB1B73A6-FB58-4BDB-AE80-48C972912121Q38180804-183B55A0-73E5-4014-9FF6-E6F7DAC8A9B4Q39894463-D3D5DAF0-1F7C-4B85-8D74-ADF1312C548CQ40308913-D84FCEE2-F63B-4F8B-8498-E7B650F3AB0FQ40521843-4E181948-D977-434A-92DE-111892B732A8
P2860
Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@ast
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@en
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@nl
type
label
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@ast
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@en
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@nl
prefLabel
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@ast
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@en
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@nl
P2093
P2860
P1476
Improved immunogenicity and pr ...... ding Ag85 by protein boosting.
@en
P2093
Dalemans W
Ottenhoff TH
Rosseels V
P2860
P304
P356
10.1128/IAI.69.5.3041-3047.2001
P407
P577
2001-05-01T00:00:00Z